loading
Iovance Biotherapeutics Inc stock is traded at $7.1325, with a volume of 12.50M. It is up +1.50% in the last 24 hours and up +41.70% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$6.98
Open:
$6.84
24h Volume:
12.50M
Relative Volume:
0.81
Market Cap:
$3.23B
Revenue:
$285.55M
Net Income/Loss:
$-353.86M
P/E Ratio:
-7.5071
EPS:
-0.9501
Net Cash Flow:
$-305.02M
1W Performance:
+10.70%
1M Performance:
+41.70%
6M Performance:
+170.42%
1Y Performance:
+177.84%
1-Day Range:
Value
$6.7031
$7.2499
1-Week Range:
Value
$6.18
$7.2499
52-Week Range:
Value
$1.76
$7.2499

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name
Name
Iovance Biotherapeutics Inc
Name
Phone
(650) 260-7120
Name
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Name
Employee
975
Name
Twitter
Name
Next Earnings Date
2026-08-06
Name
Latest SEC Filings
Name
IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
IOVA icon
IOVA
Iovance Biotherapeutics Inc
7.14 3.16B 285.55M -353.86M -305.02M -0.9501
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
515.33 128.19B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
807.80 82.72B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
992.01 53.26B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
212.13 43.66B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
362.05 39.31B 5.76B 514.49M 1.10B 4.4813

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-25-26 Upgrade Citizens Mkt Perform → Mkt Outperform
Jul-15-25 Downgrade Goldman Neutral → Sell
May-16-25 Downgrade UBS Buy → Neutral
May-12-25 Downgrade Truist Buy → Hold
May-09-25 Downgrade Citizens JMP Mkt Outperform → Mkt Perform
Oct-24-24 Initiated UBS Buy
Jul-29-24 Downgrade Piper Sandler Overweight → Neutral
Nov-20-23 Initiated Goldman Buy
Sep-18-23 Reiterated Barclays Overweight
May-30-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-27-23 Resumed Wells Fargo Equal Weight
Jan-27-23 Upgrade Piper Sandler Neutral → Overweight
Dec-09-22 Downgrade Goldman Buy → Neutral
Oct-31-22 Initiated Guggenheim Neutral
Aug-18-22 Resumed Wells Fargo Equal Weight
Jan-28-22 Upgrade Stifel Hold → Buy
Dec-07-21 Resumed Cowen Outperform
Jun-10-21 Upgrade JMP Securities Mkt Perform → Mkt Outperform
May-20-21 Downgrade Piper Sandler Overweight → Neutral
May-19-21 Downgrade JMP Securities Mkt Outperform → Mkt Perform
May-19-21 Downgrade Stifel Buy → Hold
May-03-21 Initiated Truist Buy
Apr-16-21 Initiated Goldman Buy
Mar-08-21 Upgrade H.C. Wainwright Neutral → Buy
Dec-15-20 Downgrade H.C. Wainwright Buy → Neutral
Oct-06-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-22-20 Initiated Mizuho Buy
Mar-04-20 Initiated Barclays Overweight
Feb-26-20 Reiterated H.C. Wainwright Buy
Feb-26-20 Reiterated Oppenheimer Outperform
Dec-18-19 Initiated JMP Securities Mkt Outperform
Oct-01-19 Initiated Stifel Buy
Apr-29-19 Initiated Piper Jaffray Overweight
Feb-28-19 Reiterated Chardan Capital Markets Buy
Feb-07-19 Initiated Robert W. Baird Outperform
Dec-31-18 Resumed B. Riley FBR Buy
Jul-06-18 Reiterated Chardan Capital Markets Buy
Apr-10-18 Upgrade B. Riley FBR, Inc. Neutral → Buy
Mar-13-18 Reiterated B. Riley FBR, Inc. Neutral
Feb-23-18 Downgrade B. Riley FBR, Inc. Buy → Neutral
Jan-25-18 Reiterated H.C. Wainwright Buy
Nov-01-17 Reiterated B. Riley FBR, Inc. Buy
View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

pulisher
Aug 16, 2026

Iovance Biotherapeutics, Inc. (IOVA) Latest Stock News & Headlines - Yahoo Finance

Aug 16, 2026
pulisher
Aug 16, 2026

GSA Capital Partners LLP Buys New Holdings in Iovance Biotherapeutics, Inc. $IOVA - marketbeat.com

Aug 16, 2026
pulisher
Aug 16, 2026

Bank of America Corp DE Sells 5,787,694 Shares of Iovance Biotherapeutics, Inc. $IOVA - marketbeat.com

Aug 16, 2026
pulisher
Aug 15, 2026

Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026 - The Cryptonomist

Aug 15, 2026
pulisher
Aug 15, 2026

IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits

Aug 15, 2026
pulisher
Aug 15, 2026

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits

Aug 15, 2026
pulisher
Aug 15, 2026

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance? - Yahoo Finance

Aug 15, 2026
pulisher
Aug 15, 2026

Iovance (IOVA) Q2 2026 Earnings Call Transcript - AOL.com

Aug 15, 2026
pulisher
Aug 14, 2026

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill

Aug 14, 2026
pulisher
Aug 14, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month HighHere's What Happened - marketbeat.com

Aug 14, 2026
pulisher
Aug 14, 2026

Iovance Biotherapeutics stock hits 52-week high at 6.94 USD By Investing.com - Investing.com Nigeria

Aug 14, 2026
pulisher
Aug 14, 2026

Iovance Biotherapeutics stock hits 52-week high at 6.94 USD - Investing.com

Aug 14, 2026
pulisher
Aug 14, 2026

Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Aug 14, 2026
pulisher
Aug 13, 2026

IOVA Stock Quote Price and Forecast - CNN

Aug 13, 2026
pulisher
Aug 12, 2026

IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast - 24/7 Wall St.

Aug 12, 2026
pulisher
Aug 12, 2026

Iovance Biotherapeutics (IOVA) Is Up 48.3% After Narrowing Losses And Reaffirming 2026 Revenue Guidance - Sahm

Aug 12, 2026
pulisher
Aug 11, 2026

Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns - Sahm

Aug 11, 2026
pulisher
Aug 11, 2026

Hennion & Walsh Asset Management Inc. Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA - marketbeat.com

Aug 11, 2026
pulisher
Aug 11, 2026

Iovance Biotherapeutics (IOVA) Short Interest & Short Float | Updated Aug 2026 - MarketBeat

Aug 11, 2026
pulisher
Aug 10, 2026

Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance? - Sahm

Aug 10, 2026
pulisher
Aug 10, 2026

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? - fool.com

Aug 10, 2026
pulisher
Aug 10, 2026

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? - The Motley Fool

Aug 10, 2026
pulisher
Aug 10, 2026

Why Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Back in Market Conversation? - Kalkine Media

Aug 10, 2026
pulisher
Aug 10, 2026

Weekly Recap: IOV-LUN-202 enrollment and Q2 2026 revenue jump - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Dimensional Fund Advisors LP Purchases 1,106,592 Shares of Iovance Biotherapeutics, Inc. $IOVA - marketbeat.com

Aug 10, 2026
pulisher
Aug 10, 2026

What is HC Wainwright's Forecast for IOVA Q3 Earnings? - MarketBeat

Aug 10, 2026
pulisher
Aug 09, 2026

Earnings Beat: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Moomoo

Aug 09, 2026
pulisher
Aug 08, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Aug 08, 2026
pulisher
Aug 08, 2026

Iovance Biotherapeutics Stock Price Forecast. Should You Buy IOVA? - StockInvest.us

Aug 08, 2026
pulisher
Aug 07, 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Given New $8.00 Price Target at Citizens Jmp - MarketBeat

Aug 07, 2026
pulisher
Aug 07, 2026

$Iovance Biotherapeutics (IOVA.US)$ - Moomoo

Aug 07, 2026
pulisher
Aug 07, 2026

State Street Corporation (NYSE: STT) discloses 5.5% Iovance Biotherapeutics stake - Stock Titan

Aug 07, 2026
pulisher
Aug 07, 2026

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect? - Yahoo Finance

Aug 07, 2026
pulisher
Aug 07, 2026

A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $7 to $13 - Moomoo

Aug 07, 2026
pulisher
Aug 07, 2026

Iovance Biotherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 07, 2026
pulisher
Aug 07, 2026

Form 8K Iovance Biotherapeutics Inc For: 6 August By Investing.com - Investing.com South Africa

Aug 07, 2026
pulisher
Aug 07, 2026

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 44.93% Potential Upside in Biotech Innovation - DirectorsTalk Interviews

Aug 07, 2026
pulisher
Aug 07, 2026

Iovance Biotherapeutics Inc (IOVA) Stock News Today - TradingKey

Aug 07, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highl - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 100% Upside - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highlights: Record Revenue and ... - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics stock hits 52-week high at $5.97 By Investing.com - Investing.com Nigeria

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics (NASDAQ: IOVA) files updated August 2026 presentation - Stock Titan

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics Q2 Earnings Call Highlights - MarketBeat

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next - Yahoo Finance

Aug 06, 2026
pulisher
Aug 06, 2026

IovanceStock Soars On Q2 EarningsCritical Data In Melanoma, NSCLC Due September - Seeking Alpha

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics (IOVA) Shares Surge 40% on Strong Q2; Ma - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

Earnings call transcript: Iovance beats Q2 2026 estimates, shares jump 30% - Investing.com

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance shares surge 39% as Amtagvi Q2 revenue and margins surpass expectations - TechStock²

Aug 06, 2026
pulisher
Aug 06, 2026

Iovance Biotherapeutics (IOVA) Revises 2026 Revenue Outlook Amid Strong Q2 Sales - GuruFocus

Aug 06, 2026
pulisher
Aug 06, 2026

Why Iovance Biotherapeutics (IOVA) Stock Is Up Today - Quiver Quantitative

Aug 06, 2026

Iovance Biotherapeutics Inc Stock (IOVA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Iovance Biotherapeutics Inc Stock (IOVA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Roche Corleen M.
Chief Financial Officer
Aug 06 '26
Option Exercise
0.00
49,995
0
49,995
Vogt Frederick G
Interim CEO & General Counsel
Jun 05 '26
Option Exercise
0.00
15,625
0
569,130
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Jun 05 '26
Option Exercise
0.00
7,813
0
144,087
Puri Raj K.
Chief Regulatory Officer
Jun 05 '26
Option Exercise
0.00
9,766
0
251,957
BILINSKY IGOR
Chief Operating Officer
Jun 05 '26
Option Exercise
0.00
7,813
0
137,896
Vogt Frederick G
Interim CEO & General Counsel
Jun 01 '26
Option Exercise
0.00
41,668
0
571,206
Puri Raj K.
Chief Regulatory Officer
Jun 01 '26
Option Exercise
0.00
5,469
0
244,699
GRAF FINCKENSTEIN FRIEDRICH
Chief Medical Officer
Jun 01 '26
Option Exercise
0.00
8,790
0
140,747
BILINSKY IGOR
Chief Operating Officer
Jun 01 '26
Option Exercise
0.00
8,790
0
134,556
Kirby Daniel Gordon
Chief Commercial Officer
May 11 '26
Option Exercise
0.00
10,000
0
149,381
$65.14
price up icon 3.00%
$36.17
price down icon 0.02%
$59.33
price up icon 1.31%
$127.75
price up icon 3.08%
$224.85
price down icon 1.44%
ONC ONC
$362.31
price up icon 4.41%
Cap:     |  Volume (24h):